Sanofi reported mixed Phase 2 data for lunsekimig, a bispecific nanobody targeting TSLP and IL-13, with the asset landing on efficacy in asthma and chronic rhinitis with nasal polyps but missing key endpoints in atopic dermatitis. In Phase 2 studies, lunsekimig met main and key secondary goals in moderate-to-severe asthma and reduced nasal polyp size/severity in chronic rhinosinusitis with nasal polyps, with Sanofi describing effects on flare-ups and lung function as statistically significant and clinically meaningful. In a separate Phase 2 eczema trial, the drug failed to meet its primary objective tied to skin-clearance thresholds versus placebo, while safety was described as generally consistent across studies. Sanofi is now looking to differentiate lunsekimig as a potential successor narrative alongside its broader immunology competition pressure from Dupixent-era biologics.